The importance of inflammation and inflammatory pathways in atherosclerotic disease and acute coronary syndromes (ACS) is well established. The success of statin therapy rests not only on potently reducing levels of low-density lipoprotein cholesterol, but also on the many beneficial, pleiotropic effects statin therapy has on various inflammatory mechanisms in atherosclerotic disease, from reducing endothelial dysfunction to attenuating levels of serum C-reactive 
therapeutics that target inflammatory pathways to mitigate the development of post-ACS complications.
In this review, we examine the fate of work over the past decade to develop therapeutics that target various inflammatory pathways and their components (Central Illustration). We will focus on therapeutic agents directed at the complement pathway and cleavage of C5, secretory phospholipase A 2 (sPLA2), lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), interleukin-1, and the mitogen-activated protein kinase (MAPK) signaling cascades ( Table 1) .
We examine their development from animal models and other preclinical investigations through early and late-phase randomized clinical trials that tested the experimental drugs in ACS patients. We then offer potential explanations for why work targeting these inflammatory components and pathways in ACS has not translated into therapeutic successes and describe current, promising novel therapies that are still under investigation. (12) . In another study of myocardial ischemia and reperfusion injury in rats, injection of C5 short hairpin ribonucleic acid 2 days before induction of ischemia inhibited C5 expression, significantly decreased the level of troponin T, and reduced the infarct size by 40% (13) . Additionally, in a pig model, infusion of a monoclonal antibody to C5a (at the time of onset of ischemia) followed by 50 min of occlusion of the left anterior descending artery using an occluder catheter and 3 h of reperfusion resulted in significant reduction in infarct size and reperfusion injury (14) . 
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Failure to Launch benefit was independent of infarct size, evidence of angiographic or electrocardiographic reperfusion, and extent of ST-segment elevation (17) . In addition, the composite of worsening heart failure, shock, and (20) . Despite the mortality benefit observed with pexelizumab treatment in the COMMA trial, there was no 30-or 90-day mortality benefit observed in the pexelizumab group compared with placebo in APEX AMI (Figure 2 ).
Pexelizumab was also explored as a treatment to reduce post-coronary artery bypass graft (CABG)
complications. Among patients undergoing cardiopulmonary bypass for CABG surgery, an inflammatory response involving activation of the complement system has been described (21 A subsequent meta-analysis of all 7 randomized clinical trials of pexelizumab, which included over 15,000 patients with ischemic heart disease (7,019
with STEMI and 8,177 undergoing CABG surgery),
showed no benefit of pexelizumab in STEMI (28) .
However, in the CABG subpopulation, there was a Rymer and Newby
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Based on these favorable effects on intermediate The trial was terminated early for potential harm. There was no effect of canakinumab on LDL-C, HDL-C, or non-HDL-C levels between groups. 
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Failure to Launch Based on several preclinical studies, inclacumab has also been studied in patients undergoing CABG.
Failure of saphenous vein grafts (SVGs) remains an ongoing concern for patients undergoing CABG and is 
